[{"id":"33e8128a-f5d1-4ff0-ad14-77db7205b7a6","acronym":"","url":"https://clinicaltrials.gov/study/NCT07128914","created_at":"2025-08-23T13:31:22.249Z","updated_at":"2025-08-23T13:31:22.249Z","phase":"Phase 1","brief_title":"A Clinical Study of GO306 in Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT07128914","lead_sponsor":"GeneSail Biotech (Shanghai) Co., Ltd.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"],"overall_status":"Recruiting","enrollment":" Enrollment 32","initiation":"Initiation: 07/31/2025","start_date":" 07/31/2025","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-08-19"},{"id":"2da9c54d-f433-496f-be98-f97e66600d34","acronym":"MCC-20575","url":"https://clinicaltrials.gov/study/NCT04610671","created_at":"2021-01-19T20:32:23.268Z","updated_at":"2025-02-25T16:38:06.492Z","phase":"Phase 1","brief_title":"Study of CG0070 Combined With Nivolumab in Cisplatin Ineligible Patients With MIBC","source_id_and_acronym":"NCT04610671 - MCC-20575","lead_sponsor":"H. Lee Moffitt Cancer Center and Research Institute","biomarkers":" CD8","pipe":" | ","alterations":" PD-L1 expression","tags":["CD8"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • cisplatin • cretostimogene grenadenorepvec (CG0070)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 21","initiation":"Initiation: 10/26/2020","start_date":" 10/26/2020","primary_txt":" Primary completion: 01/18/2025","primary_completion_date":" 01/18/2025","study_txt":" Completion: 01/01/2026","study_completion_date":" 01/01/2026","last_update_posted":"2025-02-06"},{"id":"d2fe552c-f100-425e-934e-b8a426721a46","acronym":"IGNYTE","url":"https://clinicaltrials.gov/study/NCT03767348","created_at":"2021-01-18T18:38:28.476Z","updated_at":"2025-02-25T14:27:51.295Z","phase":"Phase 2","brief_title":"Study of RP1 Monotherapy and RP1 in Combination With Nivolumab","source_id_and_acronym":"NCT03767348 - IGNYTE","lead_sponsor":"Replimune Inc.","biomarkers":" BRAF • MSI","pipe":" | ","alterations":" MSI-H/dMMR • BRAF mutation","tags":["BRAF • MSI"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSI-H/dMMR • BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Tudriqev (vusolimogene oderparepvec-wtpg)"],"overall_status":"Recruiting","enrollment":" Enrollment 340","initiation":"Initiation: 09/20/2017","start_date":" 09/20/2017","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2028","study_completion_date":" 12/01/2028","last_update_posted":"2025-01-24"},{"id":"e5c65e48-a957-4b92-b313-8ca9fc5212ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT03435952","created_at":"2021-01-18T16:57:22.872Z","updated_at":"2025-02-25T16:07:34.095Z","phase":"Phase 1","brief_title":"Pembrolizumab with Intratumoral Injection of Clostridium Novyi-NT","source_id_and_acronym":"NCT03435952","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Clostridium novyi-NT"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 18","initiation":"Initiation: 07/10/2018","start_date":" 07/10/2018","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2026","study_completion_date":" 10/01/2026","last_update_posted":"2024-10-31"},{"id":"54a84071-c2ad-487e-b24d-56980071bc66","acronym":"","url":"https://clinicaltrials.gov/study/NCT02068794","created_at":"2021-01-18T09:31:44.594Z","updated_at":"2024-07-02T16:34:26.660Z","phase":"Phase 1/2","brief_title":"MV-NIS Infected Mesenchymal Stem Cells in Treating Recurrent Ovarian, Primary Peritoneal or Fallopian Tube Cancer","source_id_and_acronym":"NCT02068794","lead_sponsor":"Mayo Clinic","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MV-NIS"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 34","initiation":"Initiation: 03/31/2014","start_date":" 03/31/2014","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-06-13"},{"id":"85b6b710-2ff1-4053-aee4-c2133e6bc508","acronym":"neoBREASTIM","url":"https://clinicaltrials.gov/study/NCT06067061","created_at":"2023-10-04T15:10:55.268Z","updated_at":"2024-07-02T16:34:59.994Z","phase":"Phase 1/2","brief_title":"\"neoBREASTIM\": Atezolizumab Plus RP1 Oncolytic Immunotherapy in the NeoAdjuvant Setting of Triple-Negative Breast Cancer","source_id_and_acronym":"NCT06067061 - neoBREASTIM","lead_sponsor":"Institut Curie","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tecentriq (atezolizumab) • Tudriqev (vusolimogene oderparepvec-wtpg)"],"overall_status":"Recruiting","enrollment":" Enrollment 51","initiation":"Initiation: 04/05/2024","start_date":" 04/05/2024","primary_txt":" Primary completion: 04/05/2026","primary_completion_date":" 04/05/2026","study_txt":" Completion: 04/05/2031","study_completion_date":" 04/05/2031","last_update_posted":"2024-05-30"},{"id":"a3950726-a4fc-4f10-89c7-7699eae995e5","acronym":"","url":"https://clinicaltrials.gov/study/NCT04954599","created_at":"2021-07-08T14:52:43.900Z","updated_at":"2024-07-02T16:35:08.431Z","phase":"Phase 1/2","brief_title":"Phase 1/2 Clinical Trial of CP-506 (HAP) in Monotherapy or With Carboplatin or ICI","source_id_and_acronym":"NCT04954599","lead_sponsor":"Maastricht University Medical Center","biomarkers":" BRCA1 • BRCA2","pipe":"","alterations":" ","tags":["BRCA1 • BRCA2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Tecentriq (atezolizumab) • Yervoy (ipilimumab) • carboplatin • Imfinzi (durvalumab) • Bavencio (avelumab) • Libtayo (cemiplimab-rwlc) • CP-506"],"overall_status":"Recruiting","enrollment":" Enrollment 126","initiation":"Initiation: 04/25/2023","start_date":" 04/25/2023","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 05/01/2026","study_completion_date":" 05/01/2026","last_update_posted":"2024-04-22"},{"id":"d4abf529-67b2-46e8-a739-11f0991f275a","acronym":"RTB","url":"https://clinicaltrials.gov/study/NCT03284268","created_at":"2021-01-18T16:13:30.310Z","updated_at":"2024-07-02T16:35:08.341Z","phase":"","brief_title":"Evaluate Safety and the Oncolitic Adenovirus VCN-01 Activity in Patients With Refractory Retinoblastoma","source_id_and_acronym":"NCT03284268 - RTB","lead_sponsor":"Fundació Sant Joan de Déu","biomarkers":" RB1","pipe":" | ","alterations":" RB1 mutation","tags":["RB1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RB1 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e zabilugene almadenorepvec (VCN-01)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 09/06/2017","start_date":" 09/06/2017","primary_txt":" Primary completion: 06/15/2024","primary_completion_date":" 06/15/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-04-22"},{"id":"100df7a9-71f2-4628-80e7-56222961276b","acronym":"","url":"https://clinicaltrials.gov/study/NCT02962167","created_at":"2021-01-19T13:11:56.112Z","updated_at":"2024-07-02T16:35:13.720Z","phase":"Phase 1","brief_title":"Modified Measles Virus (MV-NIS) for Children and Young Adults With Recurrent Medulloblastoma or Recurrent ATRT","source_id_and_acronym":"NCT02962167","lead_sponsor":"Sabine Mueller, MD, PhD","biomarkers":" CD4","pipe":"","alterations":" ","tags":["CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MV-NIS"],"overall_status":"Completed","enrollment":" Enrollment 34","initiation":"Initiation: 02/22/2017","start_date":" 02/22/2017","primary_txt":" Primary completion: 05/10/2023","primary_completion_date":" 05/10/2023","study_txt":" Completion: 05/10/2023","study_completion_date":" 05/10/2023","last_update_posted":"2024-03-20"},{"id":"9e7aadce-c10d-42e5-89cd-07b8fcf58f56","acronym":"","url":"https://clinicaltrials.gov/study/NCT03896568","created_at":"2021-01-18T19:11:27.737Z","updated_at":"2024-07-02T16:35:17.987Z","phase":"Phase 1","brief_title":"MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma","source_id_and_acronym":"NCT03896568","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" IDH1","pipe":" | ","alterations":" IDH wild-type","tags":["IDH1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e IDH wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e tasadenoturev (DNX-2401)"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 02/12/2019","start_date":" 02/12/2019","primary_txt":" Primary completion: 09/30/2027","primary_completion_date":" 09/30/2027","study_txt":" Completion: 09/30/2027","study_completion_date":" 09/30/2027","last_update_posted":"2024-02-23"},{"id":"918344be-dd4e-4358-a794-c4dce84f54ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT06171282","created_at":"2023-12-14T17:18:21.443Z","updated_at":"2024-07-02T16:35:26.226Z","phase":"Phase 1","brief_title":"A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors","source_id_and_acronym":"NCT06171282","lead_sponsor":"Shanghai Yunying Medical Technology","biomarkers":" IFNG • IL6 • TNFA • IL2 • IL10","pipe":"","alterations":" ","tags":["IFNG • IL6 • TNFA • IL2 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e R130"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 07/12/2023","start_date":" 07/12/2023","primary_txt":" Primary completion: 07/12/2025","primary_completion_date":" 07/12/2025","study_txt":" Completion: 07/12/2026","study_completion_date":" 07/12/2026","last_update_posted":"2023-12-14"},{"id":"22583c54-e88b-4929-8c51-cddb83c29f34","acronym":"ATLAS-IT-04","url":"https://clinicaltrials.gov/study/NCT03725605","created_at":"2023-12-09T16:26:37.013Z","updated_at":"2024-07-02T16:35:27.172Z","phase":"Phase 2","brief_title":"LTX-315 and Adoptive T-cell Therapy in Advanced Soft Tissue Sarcoma (ATLAS-IT-04)","source_id_and_acronym":"NCT03725605 - ATLAS-IT-04","lead_sponsor":"Lytix Biopharma AS","biomarkers":" IFNG","pipe":"","alterations":" ","tags":["IFNG"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Oncopore (ruxotemitide)"],"overall_status":"Completed","enrollment":" Enrollment 6","initiation":"Initiation: 12/28/2018","start_date":" 12/28/2018","primary_txt":" Primary completion: 07/02/2021","primary_completion_date":" 07/02/2021","study_txt":" Completion: 10/11/2021","study_completion_date":" 10/11/2021","last_update_posted":"2023-12-05"},{"id":"aa242778-1644-4871-9ae6-baf20f40061c","acronym":"ATLAS-IT-05","url":"https://clinicaltrials.gov/study/NCT04796194","created_at":"2021-03-12T15:53:01.676Z","updated_at":"2024-07-02T16:35:29.830Z","phase":"Phase 2","brief_title":"Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma","source_id_and_acronym":"NCT04796194 - ATLAS-IT-05","lead_sponsor":"Lytix Biopharma AS","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cisplatin • Oncopore (ruxotemitide)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-11-09"},{"id":"c7e9b9c9-d4ce-4d93-91cb-690df0a318f7","acronym":"Delivir","url":"https://clinicaltrials.gov/study/NCT05788926","created_at":"2023-03-29T14:03:17.793Z","updated_at":"2024-07-02T16:35:32.334Z","phase":"Phase 1","brief_title":"A Clinical Trial of TG6050 in Patients With Metastatic Non-Small Cell Lung Cancer (Delivir)","source_id_and_acronym":"NCT05788926 - Delivir","lead_sponsor":"Transgene","biomarkers":" EGFR • HER-2 • PD-L1 • KRAS • ALK • RET • ROS1","pipe":" | ","alterations":" BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • HER-2 mutation • RET fusion • RET mutation • ROS1 fusion • RET rearrangement • KRAS G12","tags":["EGFR • HER-2 • PD-L1 • KRAS • ALK • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • KRAS mutation • KRAS G12C • BRAF V600 • HER-2 mutation • RET fusion • RET mutation • ROS1 fusion • RET rearrangement • KRAS G12"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TG6050"],"overall_status":"Recruiting","enrollment":" Enrollment 36","initiation":"Initiation: 04/05/2023","start_date":" 04/05/2023","primary_txt":" Primary completion: 10/30/2024","primary_completion_date":" 10/30/2024","study_txt":" Completion: 03/31/2025","study_completion_date":" 03/31/2025","last_update_posted":"2023-10-20"},{"id":"befd90fe-42a7-4ced-ae3e-ff90b2e619f7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05961111","created_at":"2023-07-27T18:09:03.326Z","updated_at":"2024-07-02T16:35:41.843Z","phase":"Phase 1","brief_title":"A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT05961111","lead_sponsor":"Shanghai Yunying Medical Technology","biomarkers":" IL6 • CXCL8 • IL2 • IL10 • IL4","pipe":"","alterations":" ","tags":["IL6 • CXCL8 • IL2 • IL10 • IL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e R130"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 06/24/2023","start_date":" 06/24/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-07-27"},{"id":"69d3f93b-bc65-4950-b96a-cb0c18e1241f","acronym":"","url":"https://clinicaltrials.gov/study/NCT05886075","created_at":"2023-06-02T14:06:05.908Z","updated_at":"2024-07-02T16:35:46.614Z","phase":"Phase 1","brief_title":"A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors","source_id_and_acronym":"NCT05886075","lead_sponsor":"Shanghai Yunying Medical Technology","biomarkers":" IL6 • CXCL8 • IL2 • IL10 • IL4","pipe":"","alterations":" ","tags":["IL6 • CXCL8 • IL2 • IL10 • IL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e R130"],"overall_status":"Recruiting","enrollment":" Enrollment 24","initiation":"Initiation: 03/30/2023","start_date":" 03/30/2023","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2025","study_completion_date":" 03/01/2025","last_update_posted":"2023-06-02"},{"id":"049ebbe4-3822-4f58-b863-4709ccc7c019","acronym":"","url":"https://clinicaltrials.gov/study/NCT05860374","created_at":"2023-05-16T17:06:32.908Z","updated_at":"2024-07-02T16:35:47.882Z","phase":"Phase 1","brief_title":"A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors","source_id_and_acronym":"NCT05860374","lead_sponsor":"Shanghai Yunying Medical Technology","biomarkers":" IL6 • CXCL8 • IL2 • IL10 • IL4","pipe":"","alterations":" ","tags":["IL6 • CXCL8 • IL2 • IL10 • IL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e R130"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/02/2023","start_date":" 03/02/2023","primary_txt":" Primary completion: 03/02/2025","primary_completion_date":" 03/02/2025","study_txt":" Completion: 03/02/2026","study_completion_date":" 03/02/2026","last_update_posted":"2023-05-16"},{"id":"f8d0c3ae-87fa-414c-9eb9-d863a7bbf093","acronym":"","url":"https://clinicaltrials.gov/study/NCT05851456","created_at":"2023-05-09T14:04:41.504Z","updated_at":"2024-07-02T16:35:48.676Z","phase":"Phase 1","brief_title":"A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors","source_id_and_acronym":"NCT05851456","lead_sponsor":"Shanghai Yunying Medical Technology","biomarkers":" IL6 • CXCL8 • IL2 • IL10 • IL4","pipe":"","alterations":" ","tags":["IL6 • CXCL8 • IL2 • IL10 • IL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e R130"],"overall_status":"Recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 04/10/2023","start_date":" 04/10/2023","primary_txt":" Primary completion: 04/01/2025","primary_completion_date":" 04/01/2025","study_txt":" Completion: 04/01/2026","study_completion_date":" 04/01/2026","last_update_posted":"2023-05-09"},{"id":"4508f571-d999-49fb-aef8-b58a7b46701d","acronym":"","url":"https://clinicaltrials.gov/study/NCT05830240","created_at":"2023-04-26T14:04:49.427Z","updated_at":"2024-07-02T16:35:49.548Z","phase":"Phase 1","brief_title":"A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer","source_id_and_acronym":"NCT05830240","lead_sponsor":"Shanghai Yunying Medical Technology","biomarkers":" IL6 • CXCL8 • IL2 • IL10 • IL4","pipe":"","alterations":" ","tags":["IL6 • CXCL8 • IL2 • IL10 • IL4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e R130"],"overall_status":"Recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 03/27/2023","start_date":" 03/27/2023","primary_txt":" Primary completion: 03/27/2025","primary_completion_date":" 03/27/2025","study_txt":" Completion: 03/27/2026","study_completion_date":" 03/27/2026","last_update_posted":"2023-04-26"},{"id":"080d2484-f210-4859-8c3f-f785a07ec913","acronym":"","url":"https://clinicaltrials.gov/study/NCT01846091","created_at":"2021-01-18T08:14:01.029Z","updated_at":"2024-07-02T16:35:55.578Z","phase":"Phase 1","brief_title":"Viral Therapy In Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Cancer or Metastatic Breast Cancer","source_id_and_acronym":"NCT01846091","lead_sponsor":"Mayo Clinic","biomarkers":" HER-2 • ER • PGR","pipe":" | ","alterations":" HER-2 positive • HER-2 negative • ER positive + PGR positive • PGR positive","tags":["HER-2 • ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 negative • ER positive + PGR positive • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MV-NIS"],"overall_status":"Completed","enrollment":" Enrollment 12","initiation":"Initiation: 04/09/2013","start_date":" 04/09/2013","primary_txt":" Primary completion: 09/18/2019","primary_completion_date":" 09/18/2019","study_txt":" Completion: 11/26/2019","study_completion_date":" 11/26/2019","last_update_posted":"2023-02-14"},{"id":"fd27eba5-070d-465c-9dd7-90afaae4e124","acronym":"PV-10-NET-01","url":"https://clinicaltrials.gov/study/NCT02693067","created_at":"2021-02-11T16:53:11.341Z","updated_at":"2024-07-02T16:35:56.153Z","phase":"Phase 1","brief_title":"A Phase 1 Study of PV-10 Chemoablation of Neuroendocrine Tumours (NET) Metastatic to the Liver","source_id_and_acronym":"NCT02693067 - PV-10-NET-01","lead_sponsor":"Provectus Biopharmaceuticals, Inc.","biomarkers":" SSTR","pipe":" | ","alterations":" SSTR Expression","tags":["SSTR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e SSTR Expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Provecta (rose bengal sodium)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 07/01/2016","start_date":" 07/01/2016","primary_txt":" Primary completion: 09/01/2021","primary_completion_date":" 09/01/2021","study_txt":" Completion: 09/01/2023","study_completion_date":" 09/01/2023","last_update_posted":"2023-02-08"},{"id":"70b0b9ad-4c48-4eb5-9e7f-d4a0163de080","acronym":"K19017-004","url":"https://clinicaltrials.gov/study/NCT05684731","created_at":"2023-01-13T14:59:15.392Z","updated_at":"2024-07-02T16:35:57.631Z","phase":"Phase 1","brief_title":"Safety and Efficacy of KM1 in Subjects With Recurrent or Refractory Ovarian Cancer","source_id_and_acronym":"NCT05684731 - K19017-004","lead_sponsor":"Tongji Hospital","biomarkers":" MUC16","pipe":"","alterations":" ","tags":["MUC16"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • cisplatin • carboplatin • albumin-bound paclitaxel • KM1"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 02/01/2023","start_date":" 02/01/2023","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2026","study_completion_date":" 06/01/2026","last_update_posted":"2023-01-13"},{"id":"b8938d92-36d0-423c-9eba-e8257f8d60ee","acronym":"","url":"https://clinicaltrials.gov/study/NCT03799744","created_at":"2021-01-18T18:46:56.979Z","updated_at":"2025-02-25T15:08:14.577Z","phase":"Phase 1","brief_title":"Safety,Tolerability,and Efficacy of VCN-01 With Durvalumab in R/M Head and Neck Squamous Cell Carcinoma","source_id_and_acronym":"NCT03799744","lead_sponsor":"Institut Català d'Oncologia","biomarkers":" IL6 • IL10","pipe":"","alterations":" ","tags":["IL6 • IL10"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • zabilugene almadenorepvec (VCN-01)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 20","initiation":"Initiation: 03/20/2019","start_date":" 03/20/2019","primary_txt":" Primary completion: 01/31/2023","primary_completion_date":" 01/31/2023","study_txt":" Completion: 01/31/2023","study_completion_date":" 01/31/2023","last_update_posted":"2022-03-28"},{"id":"c5b73a52-46ba-4836-95bd-c175161b13a0","acronym":"SPICE","url":"https://clinicaltrials.gov/study/NCT02636036","created_at":"2021-04-09T00:54:47.675Z","updated_at":"2025-02-25T14:36:03.548Z","phase":"Phase 1","brief_title":"Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial Tumors","source_id_and_acronym":"NCT02636036 - SPICE","lead_sponsor":"PsiOxus Therapeutics Ltd","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • enadenotucirev (ColoAd1)"],"overall_status":"Completed","enrollment":" Enrollment 51","initiation":"Initiation: 01/25/2016","start_date":" 01/25/2016","primary_txt":" Primary completion: 10/08/2021","primary_completion_date":" 10/08/2021","study_txt":" Completion: 10/08/2021","study_completion_date":" 10/08/2021","last_update_posted":"2021-11-09"}]